375 related articles for article (PubMed ID: 18163880)
1. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
2. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
Koss B; Ryan J; Budhraja A; Szarama K; Yang X; Bathina M; Cardone MH; Nikolovska-Coleska Z; Letai A; Opferman JT
Oncotarget; 2016 Mar; 7(10):11500-11. PubMed ID: 26862853
[TBL] [Abstract][Full Text] [Related]
3. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
5. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.
Willis SN; Fletcher JI; Kaufmann T; van Delft MF; Chen L; Czabotar PE; Ierino H; Lee EF; Fairlie WD; Bouillet P; Strasser A; Kluck RM; Adams JM; Huang DC
Science; 2007 Feb; 315(5813):856-9. PubMed ID: 17289999
[TBL] [Abstract][Full Text] [Related]
7. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.
Erlacher M; Labi V; Manzl C; Böck G; Tzankov A; Häcker G; Michalak E; Strasser A; Villunger A
J Exp Med; 2006 Dec; 203(13):2939-51. PubMed ID: 17178918
[TBL] [Abstract][Full Text] [Related]
8. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
9. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
[TBL] [Abstract][Full Text] [Related]
10. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
11. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
12. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW
Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170
[TBL] [Abstract][Full Text] [Related]
13. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
Chen L; Willis SN; Wei A; Smith BJ; Fletcher JI; Hinds MG; Colman PM; Day CL; Adams JM; Huang DC
Mol Cell; 2005 Feb; 17(3):393-403. PubMed ID: 15694340
[TBL] [Abstract][Full Text] [Related]
14. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
[TBL] [Abstract][Full Text] [Related]
15. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 homology domain 3-only proteins Puma and Bim mediate the vulnerability of CA1 hippocampal neurons to proteasome inhibition in vivo.
Tsuchiya T; Bonner HP; Engel T; Woods I; Matsushima S; Ward MW; Taki W; Henshall DC; Concannon CG; Prehn JH
Eur J Neurosci; 2011 Feb; 33(3):401-8. PubMed ID: 21198986
[TBL] [Abstract][Full Text] [Related]
17. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
18. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
19. New dimension in therapeutic targeting of BCL-2 family proteins.
Besbes S; Mirshahi M; Pocard M; Billard C
Oncotarget; 2015 May; 6(15):12862-71. PubMed ID: 25970783
[TBL] [Abstract][Full Text] [Related]
20. A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity.
Ponassi R; Biasotti B; Tomati V; Bruno S; Poggi A; Malacarne D; Cimoli G; Salis A; Pozzi S; Miglino M; Damonte G; Cozzini P; Spyrakis F; Campanini B; Bagnasco L; Castagnino N; Tortolina L; Mumot A; Frassoni F; Daga A; Cilli M; Piccardi F; Monfardini I; Perugini M; Zoppoli G; D'Arrigo C; Pesenti R; Parodi S
Cell Cycle; 2008 Oct; 7(20):3211-24. PubMed ID: 18843207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
